Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07252232 · tracked via the Priya Life Science UK tracker

Sponsor

Revolution Medicines, Inc.

Phase

Phase 3

Started

2025-12-15

Last updated

2026-09-15

Condition(s) studied

Pancreatic CancerPDACPDAC - Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma (PDAC)Resected Pancreatic Adenocarcinoma

Investigational drug(s) / intervention(s)

daraxonrasib

daraxonrasib: oral tablets

Study summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * At least 18 years old and has provided informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease. * Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy. * Must have completed most recent treatment within the past 12 weeks. * Adequate organ function (bone marrow, liver, kidney, coagulation). * Documented RAS mutation status. * Able to take oral medications. Exclusion Criteria: * Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors). * Any conditions that may affect the ability to take or absorb study drug. * Major surgery within 28 days prior to randomization. * Patient is unable or unwilling to comply with protocol-required study visits or procedures.

Primary outcome measure(s)

Disease-Free Survival (DFS) per Investigator — Up to approximately 5 years
DFS defined as the time from randomization until disease recurrence or death from any cause, whichever occurs first. Recurrence is per response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by Investigator.

Trial sites (74)

Facility	City	Region	Status
Mayo Clinic	Phoenix	Arizona	Recruiting
HonorHealth Research Institute	Scottsdale	Arizona	Recruiting
UC San Diego Moores Cancer Center	La Jolla	California	Recruiting
Cedars-Sinai Cancer at Cedars-Sinai Medical Center	Los Angeles	California	Recruiting
University of California, Los Angeles	Los Angeles	California	Recruiting
Stanford Cancer Institute	Palo Alto	California	Recruiting
University of California, San Francisco	San Francisco	California	Recruiting
Rocky Mountain Cancer Centers, LLP	Lakewood	Colorado	Recruiting
Hartford Healthcare	Hartford	Connecticut	Recruiting
Mayo Clinic	Jacksonville	Florida	Recruiting
University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center	Miami	Florida	Recruiting
Florida Cancer Specialists	St. Petersburg	Florida	Recruiting
Winship Cancer Institute, Emory University	Atlanta	Georgia	Recruiting
Community Health Network	Indianapolis	Indiana	Recruiting
University of Kansas Medical Center Research Institute, Inc.	Lawrence	Kansas	Recruiting
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital	Baltimore	Maryland	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	Recruiting
Dana Farber Cancer Institute (DFCI)	Boston	Massachusetts	Recruiting
Mayo Clinic Cancer Center	Rochester	Minnesota	Recruiting
Saint Luke's Cancer Institute	Kansas City	Missouri	Recruiting
University of Nebraska Medical Center	Omaha	Nebraska	Recruiting
Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada	Recruiting
Laura and Issac Perlmutter Cancer Center at NYU Langone-Ambulatory Care Center	New York	New York	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	Recruiting
Columbia University Medical Center	New York	New York	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	Recruiting
University of Rochester Medical Center	Rochester	New York	Recruiting
Duke Cancer Center	Durham	North Carolina	Recruiting
Taylor Cancer Research Center	Maumee	Ohio	Recruiting
University of Pennsylvania, Abramson Cancer Center	Philadelphia	Pennsylvania	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	Recruiting
Avera Cancer Institute	Sioux Falls	South Dakota	Recruiting
SCRI Oncology Partners	Nashville	Tennessee	Recruiting
Texas Oncology - DFW	Dallas	Texas	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	Not Yet Recruiting
Texas Oncology - Northeast Texas	Longview	Texas	Recruiting
University of Utah, Huntsman Cancer Institute	Salt Lake City	Utah	Recruiting
Virginia Cancer Specialists	Fairfax	Virginia	Recruiting
Fred Hutchison Cancer Center	Seattle	Washington	Recruiting
Froedtert Hospital and the Medical College of Wisconsin	Milwaukee	Wisconsin	Recruiting

+ 34 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07252232 on ClinicalTrials.gov ↗ ← All trials in the UK